MBRX: Breaking News — Early Miracle Data Surpasses Expectations

Don't want emails from us anymore? Unsubscribe here *Sponsored By TD Media LLC* This information is disseminated on behalf of Moleculin Biotech, Inc. News Out! Moleculin's MIRACLE Trial Delivers Early 40% Remission Signal in AML — A Potential Turning Point Moleculin Biotech, Inc. (Nasdaq: MBRX) just delivered early data from its pivotal MIRACLE trial that's turning heads in the biotech world  In the first 30 evaluable patients, its lead drug Annamycin produced a 40% preliminary composite remission rate in relapsed/refractory AML — a result that meaningfully outpaces historical benchmarks for standard therapy.  With enrollment continuing and the next data unblinding expected in Q2 2026, this emerging efficacy signal positions Moleculin at a potentially transformative moment in its clinical development story. Read full article here  Moleculin Biotech, Inc. (Nasdaq: MBRX) is entering a high-impact stretch as it strengthens global intellectual property protection, advances its pivotal MIRACLE Phase 3 AML trial, and expands its oncology pipeline.  The company recently secured a notice of allowance in Japan for a key Annamycin patent, reinforcing commercial protection across major markets. At the same time, an independent expert review of 90 treated patients confirmed no evidence of cardiotoxicity — a critical differentiator for Annamycin, which is designed to become the first non-cardiotoxic anthracycline.  With FDA Fast Track and multiple Orphan Drug designations already in place, the regulatory pathway is clearly defined. Meanwhile, the global MIRACLE trial continues expanding across nine countries, with interim unblindings expected in 2026 that could provide early insight into efficacy and dose selection.  Beyond AML, Annamycin is preparing to enter pancreatic cancer trials, while WP1066 advances in brain tumor studies with encouraging early data. Biotech stocks often fly under the radar, but MBRX's expanding global footprint and transformative pipeline make it a company worth watching closely. With patent expansion, safety validation, Phase 3 momentum, and multiple upcoming catalysts, this tiny NASDAQ firm is transitioning into a potentially value-defining period — learn how MBRX is positioning itself for a pivotal 2026 ­ Disclaimer Guy Stocks, a subsidiary of Organized Noise, LLC press releases, research reports, company profiles and other investor relations materials, publications or presentations, including web content (investor awareness services), are based on publicly available data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Furthermore, some of the content in this publication or website may contain forward-looking statements found in information made publicly available by the companies we highlight. This forward looking information fits within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding future possible events, expected continual growth of a company, the potential value of its securities, and look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. We therefore strongly encourage that you visit and review any and all financial information made publicly available by highlighted companies.  Any opinions expressed in Guy Stocks reports, company profiles, or other investor relations materials and presentations are subject to change, are expressed and given as of the date of publication, and we disclaim any obligation to advise you of any change in any information contained herein. Guy Stocks and its affiliates may buy and sell shares of securities or options and warrants of the companies mentioned in this publication or website at any time but are not and will not at any time become affiliates or owners of more than 5% of the issued and outstanding stock of the highlighted companies.  The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, Guy Stocks, its affiliates, specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Stock market investing is inherently risky. Guy Stocks and its affiliates are not responsible for any gains or losses that result from the opinions expressed in press releases, on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Securities Commission ("OSC") at www.osc.gov.on.ca. and/or the British Columbia Securities Commission ("BCSC") at https://www.bcsc.bc.ca/. Guy Stocks and Organized Noise LLC have been retained by TD Media LLC to perform promotional and advertising services for a limited time for Moleculin Biotech, Inc. (Nasdaq: MBRX), and has received cash compensation of $10,000 beginning on 2/18/26 for the period ended 2/18/26 from TD Media LLC related to the engagement of investor awareness services for Moleculin Biotech, Inc. (Nasdaq: MBRX). Guy Stocks, Organized Noise LLC and its partners and affiliates may buy and sell shares of securities or options and warrants of the companies mentioned on this website at any time. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. Guy Stocks investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services based on the publicly available information of our clients and prepared by our partners.    1389 Center Dr Park City UT 84098 USA   UNSUBSCRIBE ­